Fundraising Fox
Unicycive Therapeutics
NASDAQ: UNCYLos Altos, US · Founded 2016 · Delaware corporation · 23 employees on LinkedIn
Find your way into Unicycive Therapeutics
Sign up to see every warm intro you have to Unicycive Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Unicycive Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Unicycive is a biotechnology company that develops therapies for patients with kidney disease, identifying overlooked technologies and advancing them into commercial treatments. It focuses on unmet needs in kidney health.
Founders & leadership
Unicycive Therapeutics was founded in 2016 by Shalabh Gupta.
SG
Shalabh GuptaFounder, Chairman and CEOShalabh Gupta is a physician who founded and has led Unicycive Therapeutics since 2016, guiding the company to a Nasdaq public listing in 2021. He holds experience in business development and venture capital in the healthcare sector.
JT
John TownsendChief Financial OfficerJohn Townsend is Chief Financial Officer at Unicycive Therapeutics, a biotechnology company developing therapies for kidney disease. He brings 18 years of experience in financial reporting, accounting analysis, budgeting, and internal controls, with prior roles including controller-level positions at Cytori.
SL
Sandeep LaumasNamed on SEC filing
JR
John RyanNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$81.7M disclosed across 5 rounds · 2019–2024
▶$50MraisedMar 2024 · 25 investors · BiotechnologyRule 506(b)
▶$50MraisedMar 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John RyanDirector
- Gaurav AggarwalDirector
- Sara Kenkare-MitraDirector
- Sandeep LaumasDirector
- John TownsendExecutive Officer
- Shalabh GuptaExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $3.5M
- Placement agents
- Leerink Partners LLC, Piper Sandler & Co.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.2MraisedMar 2023 · 20 investors · BiotechnologyRule 506(b)
▶$30.2MraisedMar 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sandeep LaumasDirector
- John TownsendExecutive Officer
- John RyanDirector
- Shalabh GuptaExecutive Officer, Director
- Brigitte SchillerDirector
- Gaurav AggarwalDirector
- Offering amount
- $30.2M
- Amount sold
- $30.2M
- Sales commissions
- $1.6M
- Placement agents
- EF Hutton, division of Benchmark Investments LLC
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$604.1KraisedJun 2020 · 15 investors · BiotechnologyRule 506(b)
▶$604.1KraisedJun 2020 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John RyanDirector
- Shalabh GuptaExecutive Officer
- Sandeep LaumasDirector
- Offering amount
- $604.1K
- Amount sold
- $604.1K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$527KraisedAug 2019 · 9 investors · BiotechnologyRule 506(b)
▶$527KraisedAug 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shalabh GuptaExecutive Officer
- John RyanDirector
- Sandeep LaumasDirector
- Offering amount
- $527K
- Amount sold
- $527K
- Minimum investment
- $50K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$420KraisedMar 2019 · 8 investors · BiotechnologyRule 506(b)
▶$420KraisedMar 2019 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shalabh GuptaExecutive Officer, Director
- Sandeep LaumasDirector
- John RyanDirector
- Offering amount
- $420K
- Amount sold
- $420K
- Minimum investment
- $50K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Unicycive Therapeutics do?
- Unicycive is a biotechnology company that develops therapies for patients with kidney disease, identifying overlooked technologies and advancing them into commercial treatments. It focuses on unmet needs in kidney health.
- Who founded Unicycive Therapeutics?
- Unicycive Therapeutics was founded by Shalabh Gupta in 2016.
- How much funding has Unicycive Therapeutics raised?
- Unicycive Therapeutics has disclosed $81.7M raised across 5 rounds.
- Where is Unicycive Therapeutics headquartered?
- Unicycive Therapeutics is headquartered in Los Altos, US.